Serologically assessed markers of fibroblast activity (PRO-C3 and PRO-C6) and risk assessment of pulmonary fibrosis following severe COVID-19 infection
This study found that PRO-C3 and PRO-C6 are associated with changes in lung function after severe COVID-19 infection. High levels of both PRO-C6 and PRO-C3 were found up to 6 months after discharge in patients with impaired lung function, however, the values declined towards reference levels after 12 months.
Authors
- Thomas Hildebrandt (ORCID: https://orcid.org/0000-0001-7845-9899)
- Rikke Borg (ORCID: https://orcid.org/0000-0002-2283-3578)
- Alejandro E. Mayorca‐Guiliani (ORCID: https://orcid.org/0000-0001-8137-4722)
- Kirsten Brændholt Rasmussen
- Diana Julie Leeming (ORCID: https://orcid.org/0000-0002-4256-140X)
- M.A. Karsdal (ORCID: https://orcid.org/0000-0001-5026-8740)
- Carsten Sloth
- Anne Orholm Nielsen (ORCID: https://orcid.org/0000-0001-6529-0211)
- Henning B. Nielsen (ORCID: https://orcid.org/0000-0003-3533-8098)
- Frederikke Bay Toft
Institutions
- University of Copenhagen (DK)
- Gentofte Hospital (DK)
- Rigshospitalet (DK)
- Zealand University Hospital (DK)
- Nordic Bioscience (Denmark) (DK)
Publication Details
- Journal
- European Clinical Respiratory Journal
- Published
- 2025-05-29
- DOI
- https://doi.org/10.1080/20018525.2025.2510032
- Citations
- 1
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Boehringer Ingelheim
- Sjællands Universitetshospital